China is Flying High Again: Cirium Survey Shows Remarkable Consumer Confidence for a Travel Restart
21.10.2021 05:00:00 EEST | Business Wire | Press release
Chinese travelers are leading the airline travel recovery, with 96% intending to travel, according to a new survey by Cirium, the aviation analytics company. 81% of respondents say they plan to fly at least once within the next 12 months and 50% plan to fly by this autumn. Of those planning to travel, 73% stated it was for leisure with only 24% planning business travel.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211020005941/en/
Cirium's new Traveler Intelligence Report reveals China is flying high again. (Graphic: Business Wire)
The pent-up demand is also reflected in China’s passenger traffic, which is showing signs of a strong recovery. As of September 2021, China traffic was at 87% of 2019 levels — way ahead the rest of Asia (42%).
The survey revealed that two thirds (66%) of Chinese travelers have taken a domestic flight since the start of the pandemic. Cirium schedules data reveal domestic travel in Q4 is primed to outpace pre-pandemic levels, growing by some 15% compared to Q4 2019.
Following months of restrictions aligned to China’s Zero-COVID policy, pent-up demand for a major return to international and regional travel is palpable.
More than half (61%) of respondents shared that they are ready to travel out of mainland China once borders are open, with Southeast Asia as the region of choice, followed by Europe, Australia/New Zealand and East Asia.
Jeremy Bowen, CEO at Cirium said: “The Cirium survey highlights the Chinese traveler’s confidence in flying domestically and pent-up demand when it comes to flying internationally. There is a clear preference for Southeast Asia, so the challenge faced is to bring back travel to other markets such as East Asia, which was a previous top destination.”
“The results also show the importance of health and safety measures, which will need to be in place to increase the confidence in traveling internationally from China.”
While Chinese travelers show confidence in flying again, 35% of those surveyed claimed that they would be less likely to travel by air, post-pandemic. They were principally concerned over health, hygiene and safety.
Almost all of the respondents (96%) support the mandatory requirement to wear a face mask when travelling by air. And over 85% support the introduction of health passports as a prerequisite to flying, and the use of apps that promote touchless travel.
When choosing an airline, respondents placed importance on mandatory mask wearing (66%), improved cleaning processes in place (65%) and proof of negative pre-departure COVID-19 test (62%).
Chinese travelers were divided when it came to the time spent at the airport. 53% of travelers claimed they will reduce the amount of time they spend at airports, compared to 21% who will look to increase their time at the airport as they feel safer with the COVID-19 safety measures in place.
The survey was carried out by independent market intelligence firm AudienceNet on behalf of Cirium. The firm interviewed over 2,060 adults in mainland China between August 30 and September 8, 2021. The margin of error in the reported data did not exceed +/-3% at the 95% confidence level.
Click here to read the full China Cirium Traveler Intelligence Report.
Additional insights on air travel in the full report include:
- The importance of flying on modern aircraft
- Future use of airport lounges
- Cabin class preferences
- Top destinations outside of mainland China
Ends
For further information please follow Cirium updates on WeChat or visit www.cirium.com.
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211020005941/en/
Contact information
For media enquiries please contact:
June Lee (APAC) / Rachel Humphries (Global)
media@cirium.com
Mindy Wang (China) at Dan Communications
shumei.wang@cirium.com
Kyoko Ishida (Japan) at Train Tracks
cirium@traintracks.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom